New Releases from NCBI BookshelfDostarlimab (endometrial cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-143 [Internet].Dostarlimab (endometrial cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-143 [Internet].By admin / January 8, 2025 Post Content
